These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35906608)

  • 1. Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study.
    Cances C; Vlodavets D; Comi GP; Masson R; Mazurkiewicz-Bełdzińska M; Saito K; Zanoteli E; Dodman A; El-Khairi M; Gorni K; Gravestock I; Hoffart J; Scalco RS; Darras BT;
    Orphanet J Rare Dis; 2022 Jul; 17(1):300. PubMed ID: 35906608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
    Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
    Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
    Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
    N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risdiplam: A Review in Spinal Muscular Atrophy.
    Paik J
    CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
    Mercuri E; Deconinck N; Mazzone ES; Nascimento A; Oskoui M; Saito K; Vuillerot C; Baranello G; Boespflug-Tanguy O; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Staunton H; Yeung WY; Martin C; Fontoura P; Day JW;
    Lancet Neurol; 2022 Jan; 21(1):42-52. PubMed ID: 34942136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risdiplam in Type 1 Spinal Muscular Atrophy.
    Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
    N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
    Oskoui M; Day JW; Deconinck N; Mazzone ES; Nascimento A; Saito K; Vuillerot C; Baranello G; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Papp G; Gorni K; Kletzl H; Martin C; McIver T; Scalco RS; Staunton H; Yeung WY; Fontoura P; Mercuri E;
    J Neurol; 2023 May; 270(5):2531-2546. PubMed ID: 36735057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of infantile-onset spinal muscular atrophy.
    Kolb SJ; Coffey CS; Yankey JW; Krosschell K; Arnold WD; Rutkove SB; Swoboda KJ; Reyna SP; Sakonju A; Darras BT; Shell R; Kuntz N; Castro D; Parsons J; Connolly AM; Chiriboga CA; McDonald C; Burnette WB; Werner K; Thangarajh M; Shieh PB; Finanger E; Cudkowicz ME; McGovern MM; McNeil DE; Finkel R; Iannaccone ST; Kaye E; Kingsley A; Renusch SR; McGovern VL; Wang X; Zaworski PG; Prior TW; Burghes AHM; Bartlett A; Kissel JT;
    Ann Neurol; 2017 Dec; 82(6):883-891. PubMed ID: 29149772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
    Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
    Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 13. Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.
    Aponte Ribero V; Martí Y; Batson S; Mitchell S; Gorni K; Gusset N; Oskoui M; Servais L; Sutherland CS
    Neurology; 2023 Nov; 101(21):e2103-e2113. PubMed ID: 37813581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction.
    Bjelica B; Wohnrade C; Cespedes I; Osmanovic A; Schreiber-Katz O; Petri S
    BMC Neurol; 2024 Feb; 24(1):67. PubMed ID: 38368338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
    Erdos J; Wild C
    Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.
    Wadman RI; Wijngaarde CA; Stam M; Bartels B; Otto LAM; Lemmink HH; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    Eur J Neurol; 2018 Mar; 25(3):512-518. PubMed ID: 29194869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
    Paracha N; Hudson P; Mitchell S; Sutherland CS
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):11-38. PubMed ID: 34761360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.
    Zerres K; Rudnik-Schöneborn S; Forrest E; Lusakowska A; Borkowska J; Hausmanowa-Petrusewicz I
    J Neurol Sci; 1997 Feb; 146(1):67-72. PubMed ID: 9077498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.